Single-shot J&J vaccine effective against delta and beta variants: Study
A real-world study of South African health care workers found that the single-shot Johnson & Johnson vaccine was highly effective against the delta and beta variants, according to the South African Medical Research Council, which presented the results Friday.
The vaccine was between 91% and 96% effective against death, according the study, which included more than 477,000 health care workers. J&J showed stronger protection against the delta variant, now dominant in the United States and South Africa, than it showed against the beta variant.
"The data reported today by South African investigators show that a single shot can protect against death due to COVID-19 in the most challenging epidemiologic setting: A massive delta surge in Africa," said Dr. Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, who helped invent the J&J shot but was not directly involved in the South Africa study.
![PHOTO: A health worker talks to a vaccine trials' volunteer before he is tested for COVID-19 and participates in the country's clinical trial for potential vaccines at the Wits RHI Shandukani Research Centre in Johannesburg, South Africa, Aug. 27, 2020.](https://s.abcnews.com/images/International/jj-vaccine-trial-rt-rc-210806_1628267240342_hpMain.jpg)
While the results have not yet been published in a peer-reviewed journal, they may serve as a reassuring data point as the delta variant sweeps the U.S.
Glenda Gray, president and CEO of the South African Medical Research Council, who led the study, said at the Friday press conference that the J&J vaccine showed good durability, an indication that there's no need for booster shots just yet.
-ABC News' Sony Salzman.